{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/SLS",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nSELLAS Life Sciences Group, Inc. is listed on NASDAQ under ticker SLS. Its ISIN is US81642T2096 and its LEI is 549300VZIH50VYURLQ98. Its security type is Corporate, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its segment is not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 41 filings in the twelve months to 2026-11-08, across 25 filing days. The median gap between filing days is 7.5 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-10-27 and is a regulatory filing, 12 days before the record date. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days.\n\n## Auditor\n\nThe auditor of record is Baker Tilly US, LLP, of San Jose, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names three research houses: A.G.P., Ladenburg Thalmann & Co. Inc., and Maxim Group.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for this issuer. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n10 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001390478.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/SLS (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.sellaslifesciences.com/analyst-coverage/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/SLS (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm",
    "state": "sourced",
    "value": "Baker Tilly US, LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm",
    "state": "sourced",
    "value": "23"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm",
    "state": "sourced",
    "value": "San Jose, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/SLS",
  "coverage": {
   "count": 3,
   "houses": [
    {
     "analyst": "James Molloy",
     "house": "A.G.P.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.sellaslifesciences.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Aydin Huseynov MD CFA",
     "house": "Ladenburg Thalmann & Co. Inc.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.sellaslifesciences.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Jason McCarthy PHD",
     "house": "Maxim Group",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.sellaslifesciences.com/analyst-coverage/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.sellaslifesciences.com/analyst-coverage/",
     "result": "read: 3 of 6 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 2,
    "director_change": 1,
    "directors_dealings": 12,
    "prospectus": 1,
    "regulatory_filing": 12,
    "results": 10
   },
   "cadence_median_gap_days": 7.5,
   "filing_days": 25,
   "filings": 41,
   "latency_days": 12,
   "latest": [
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-10-27",
     "source": "https://www.sec.gov/Archives/edgar/data/1390478/000201238326003844/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "8-K",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-20260811.htm",
     "title": "8-K — 8-K (items 2.02,9.01)",
     "type": "results"
    },
    {
     "category": "10-Q",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000012/sls-20260630.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "SCHEDULE 13G",
     "date": "2026-08-07",
     "source": "https://www.sec.gov/Archives/edgar/data/1390478/000009375126000539/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    },
    {
     "category": "SCHEDULE 13G",
     "date": "2026-07-31",
     "source": "https://www.sec.gov/Archives/edgar/data/1390478/000210011926001315/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-10-27",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/SLS",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US81642T2096"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001390478.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US81642T2096)",
    "state": "sourced",
    "value": "549300VZIH50VYURLQ98"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001390478.json",
    "state": "sourced",
    "value": "SELLAS Life Sciences Group, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001390478.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001390478.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "SLS"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:de8ce145d931fee28b1f93f825440765338a836f5848ce6fb2d5b761c126e6c0",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/SLS",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:de8ce145d931fee28b1f93f825440765338a836f5848ce6fb2d5b761c126e6c0",
 "path": "/us/NASDAQ/SLS",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "SELLAS Life Sciences Group, Inc. is listed on NASDAQ under ticker SLS. Its ISIN is US81642T2096 and its LEI is 549300VZIH50VYURLQ98. Its security type is Corporate, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its segment is not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 41 filings in the twelve months to 2026-11-08, across 25 filing days. The median gap between filing days is 7.5 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-10-27 and is a regulatory filing, 12 days before the record date. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Baker Tilly US, LLP, of San Jose, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names three research houses: A.G.P., Ladenburg Thalmann & Co. Inc., and Maxim Group.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for this issuer. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "10 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001390478.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/SLS"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.sellaslifesciences.com/analyst-coverage/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/SLS"
  }
 ],
 "title": "SELLAS Life Sciences Group, Inc. (SLS) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}